Royalty Pharma plc

Royalty Pharma acquires biopharmaceutical royalties and finances life sciences innovation. The company collaborates with academic institutions, non-profit organizations, biotechnology firms, and global pharmaceutical corporations across the biopharmaceutical development spectrum. Its primary offerings comprise third-party royalties on approved medicines, synthetic royalties created on late-stage candidates, and complementary capital arrangements including unsecured debt, equity investments, and launch funding. The company generates receipts from rights tied directly to end-market sales of commercial treatments across diverse therapeutic fields such as rare diseases, oncology, immunology, neuroscience, and respiratory care.

The business manages a portfolio encompassing more than 35 commercial therapies and 20 development-stage candidates. Its underlying royalty agreements grant exposure to global pharmaceutical sales across international territories, including the United States, non-U.S. markets, and early-stage licensing opportunities in China, though certain specific interests exclude territories such as China. The provided text does not identify the location of the company's corporate headquarters.

Summary of the business section of Royalty Pharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 100 employees.”